NO20063137L - Tricykliske indolhydroksyetylaminderivater og deres anvendelse i behandlingen av Alzheimers sykdom - Google Patents

Tricykliske indolhydroksyetylaminderivater og deres anvendelse i behandlingen av Alzheimers sykdom

Info

Publication number
NO20063137L
NO20063137L NO20063137A NO20063137A NO20063137L NO 20063137 L NO20063137 L NO 20063137L NO 20063137 A NO20063137 A NO 20063137A NO 20063137 A NO20063137 A NO 20063137A NO 20063137 L NO20063137 L NO 20063137L
Authority
NO
Norway
Prior art keywords
disease
treatment
alzheimer
beta
tricyclic indole
Prior art date
Application number
NO20063137A
Other languages
English (en)
Inventor
Sally Redshaw
Emmanuel Hubert Demont
David R Vesey
Daryl Simon Walter
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20063137L publication Critical patent/NO20063137L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Det beskrives nye hydroksyetylaminforbindelser med Asp2 (P-sekretase-, BACE1- eller memapsin-) inhibitorisk aktivitet med formel (I). Videre beskrives fremgangsmåter for deres fremstilling, preparater inneholdende forbindelsene og deres anvendelse ved behandling av sykdommer som karakteriseres ved forhøyede P-amyloidnivåer eller P-amyloidavsetninger og særlig Alzheimers sykdom. Forbindelsene presenteres ved formel (I) der blant annet A-B betyr -NR5-SO2- eller NR5-CO-; R5 betyr hydrogen, C1-6 alkyl, C3-6 alkenyl, C3-6 alkynyl, C3-10 cykloalkyl, C0-6 alkylaryl, C0-6 alkylheteroaryl, C0-6 alkylheterocyklyl, C3-10 cykloalkylaryl eller C3-10 cykloalkyl-heteroaryl; W betyr -CH2-, -(CH2)2-, -(CH2)3-, -C(H)=C(H)- eller -CH2-C(H)=C(H)-; X-Y-Z betyr -C=CR8-NR9-;
NO20063137A 2003-12-12 2006-07-06 Tricykliske indolhydroksyetylaminderivater og deres anvendelse i behandlingen av Alzheimers sykdom NO20063137L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0328900.6A GB0328900D0 (en) 2003-12-12 2003-12-12 Novel compounds
PCT/EP2004/014076 WO2005058915A1 (en) 2003-12-12 2004-12-09 Tricyclic indole hydroxyethylamine derivatives and their use in the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
NO20063137L true NO20063137L (no) 2006-08-31

Family

ID=30130158

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063137A NO20063137L (no) 2003-12-12 2006-07-06 Tricykliske indolhydroksyetylaminderivater og deres anvendelse i behandlingen av Alzheimers sykdom

Country Status (17)

Country Link
US (1) US20070073060A1 (no)
EP (1) EP1692143B1 (no)
JP (1) JP2007513913A (no)
KR (1) KR20060121164A (no)
CN (1) CN1914214A (no)
AT (1) ATE414090T1 (no)
AU (1) AU2004299231A1 (no)
BR (1) BRPI0417476A (no)
CA (1) CA2549072A1 (no)
DE (1) DE602004017777D1 (no)
GB (1) GB0328900D0 (no)
IL (1) IL175819A0 (no)
IS (1) IS8521A (no)
MA (1) MA28241A1 (no)
NO (1) NO20063137L (no)
RU (1) RU2006124863A (no)
WO (1) WO2005058915A1 (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2558034A1 (en) 2004-03-09 2005-09-22 Elan Pharmaceuticals, Inc. Substituted hydroxyethylamine aspartyl protease inhibitors
CA2573138A1 (en) 2004-07-09 2006-01-26 Elan Pharmaceuticals Inc. Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
EP1794115A2 (en) * 2004-09-21 2007-06-13 Pfizer Products Incorporated N-ethyl hydroxyethylamines useful in treating cns conditions
GB0422766D0 (en) * 2004-10-13 2004-11-17 Glaxo Group Ltd Novel compounds
GB0422765D0 (en) * 2004-10-13 2004-11-17 Glaxo Group Ltd Novel compounds
WO2007047305A1 (en) * 2005-10-12 2007-04-26 Elan Pharmaceuticals, Inc. Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
US7838676B2 (en) * 2005-11-21 2010-11-23 Amgen Inc. Beta-secretase modulators and methods of use
US7872009B2 (en) 2005-11-21 2011-01-18 Amgen Inc. Beta-Secretase modulators and methods of use
FR2919289B1 (fr) * 2007-07-27 2009-09-04 Sanofi Aventis Sa Derives de 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]- diazepine-7-carboxamides, leur preparation et leur application en therapeutique.
FR2919286A1 (fr) 2007-07-27 2009-01-30 Sanofi Aventis Sa Derives de derives de 1-oxo-1,2-dihydroisoquinoleine-5- carboxamides et de 4-oxo-3,4-dihydroquinazoline-8- carboxamides,leur preparation et leur application en therapeutique.
FR2919285B1 (fr) 2007-07-27 2012-08-31 Sanofi Aventis Derives de 1-oxo-isoindoline-4-carboxamides et de 1-oxo- 1,2,3,4-tetrahydroisoquinoleine-5-carboxamides, leur preparation et leur application en therapeutique.
FR2919288B1 (fr) * 2007-07-27 2009-09-04 Sanofi Aventis Sa Derives de 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6- carboxamides, leur preparation et leur application en therapeutique.
DK2185561T3 (da) * 2007-07-27 2011-10-10 Sanofi Sa Derivater af 1,2,3,4-tetrahydropyrrolo(1,2-a)pyrazin-6-carboxamid og 2,3,4,5-tetrahydroprrolo(1,2-a)-diazepin-7-carboxamid, fremstilling deraf og terapeutisk anvendelse deraf
US8124600B2 (en) * 2008-05-29 2012-02-28 Albany Molecular Research, Inc. 5-HT3 receptor modulators, methods of making, and use thereof
FR2960876B1 (fr) 2010-06-03 2012-07-27 Sanofi Aventis Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique.
US9045445B2 (en) 2010-06-04 2015-06-02 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
WO2014031873A2 (en) * 2012-08-24 2014-02-27 Treventis Corporation Benzofurazan anti-amyloid compounds and methods
US11214579B2 (en) * 2017-10-13 2022-01-04 Purdue Research Foundation BACE1 inhibitors for the treatment of Alzheimer's disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2280096A1 (en) * 1997-02-04 1998-08-06 The Regents Of The University Of California Nanomolar, non-peptide inhibitors of cathepsin d
US6207664B1 (en) * 1998-11-25 2001-03-27 Pfizer Inc. Squalene synthetase inhibitor agents
DE60124080T2 (de) * 2000-03-23 2007-03-01 Elan Pharmaceuticals, Inc., San Francisco Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
CN1217920C (zh) * 2000-06-30 2005-09-07 艾兰制药公司 治疗早老性痴呆的化合物
EA200400648A1 (ru) * 2001-11-08 2005-04-28 Элан Фармасьютикалз, Инк. N, n'-замещенные производные 1,3-диамино-2-гидроксипропана
GB0228410D0 (en) * 2002-12-05 2003-01-08 Glaxo Group Ltd Novel Compounds
GB0309221D0 (en) * 2003-04-23 2003-06-04 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
CN1914214A (zh) 2007-02-14
MA28241A1 (fr) 2006-10-02
JP2007513913A (ja) 2007-05-31
DE602004017777D1 (de) 2008-12-24
KR20060121164A (ko) 2006-11-28
IS8521A (is) 2006-06-26
RU2006124863A (ru) 2008-01-20
GB0328900D0 (en) 2004-01-14
IL175819A0 (en) 2006-10-05
WO2005058915A1 (en) 2005-06-30
AU2004299231A1 (en) 2005-06-30
CA2549072A1 (en) 2005-06-30
ATE414090T1 (de) 2008-11-15
EP1692143B1 (en) 2008-11-12
US20070073060A1 (en) 2007-03-29
BRPI0417476A (pt) 2007-05-08
EP1692143A1 (en) 2006-08-23

Similar Documents

Publication Publication Date Title
NO20063137L (no) Tricykliske indolhydroksyetylaminderivater og deres anvendelse i behandlingen av Alzheimers sykdom
NO20053263D0 (no) Hydroksyetylaminderivater for behandling av Alzheimers sykdom.
CY1111086T1 (el) Παραγωγα 2-αμινο-κιναζολινης χρησιμα ως αναστολεις της βητα-σεκρετασης (bace)
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
CY1111070T1 (el) Παραγωγα 2-αμινο-κουιναζολινης χρησιμα ως αναστολεις της β-σεκρετασης (bace)
BRPI0409622A (pt) derivados tricìclicos de indol e o seu uso no tratamento da doença de alzheimer
WO2004080376A3 (en) Hydroxyethylamine compounds having asp2 inhibitory activity for the treatment of alzheimer’s disease
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
EP1673078A4 (en) BENZYL ETHER AND BENZYLAMINO BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE
ATE517861T1 (de) Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
EP1817312A4 (en) MACROCYCLIC AMINIOPYRIDYL BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF MORBUS ALZHEIMER
WO2006055434A3 (en) Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease
ATE538796T1 (de) Piperidin- und pyrrolidin-beta-secretase-hemmer zur behandlung von alzheimer-krankheit
WO2007019078A3 (en) Tricyclic beta-secretase inhibitors for the treatment of alzheimer's disease
ATE519740T1 (de) Tetrahydroindolderivate zur behandlung von alzheimer-krankheit
EP1912963A4 (en) CYCLIC KETALS AS BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application